Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.47 |
| ▸ | CCKAR | P32238 | 7/20 | 0.43 |
| ▸ | CCKBR | P32239 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21936997 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL25742988 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL21936996 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL17856855 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL13024331 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL25851778 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL25850145 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL12806465 | 0.98 | GLP1R (0.66) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL12806453 | 0.98 | GLP1R (0.66) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL29324606 | 0.94 | GLP1R (0.73) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129788-A1 | GLP-1/GLP-2 DUAL AGONISTS | ZEALAND PHARMA A/S (DK) | 2023-04-27 | — | — | US | disclosed |
| US-11111285-B2 | Glucagon-GLP-1-GIP triple agonist compounds | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20190270789-A1 | GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2019-09-05 | — | — | US | disclosed |
| WO-2016066744-A2 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2016-05-06 | — | — | WO | disclosed |
| US-20130058999-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN PEPTIDES | NOVO NORDISK A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20120196800-A1 | STABLE NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN | NOVO NORDISK A/S (DK) | 2012-08-02 | — | — | US | disclosed |
| US-20110213131-A1 | Method of Acylating a Peptide or Protein | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130058999-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN PEPTIDES | IAPP, VIP, INSR | GLP1R 4/4885NOD1 756/4885CCKAR 144/4885 |
| US-20230129788-A1 | GLP-1/GLP-2 DUAL AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 906/4885CCKAR 31/4885 |
| US-11111285-B2 | Glucagon-GLP-1-GIP triple agonist compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1654/4885CCKAR 20/4885 |
| US-20190270789-A1 | GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1654/4885CCKAR 20/4885 |
| US-20120196800-A1 | STABLE NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN | IAPP, INSR, PNLIP | GLP1R 37/4885NOD1 2386/4885CCKAR 799/4885 |
| US-20110213131-A1 | Method of Acylating a Peptide or Protein | DNPEP, PTMA, ANPEP | GLP1R 2584/4885NOD1 4174/4885CCKAR 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.